Cost effectiveness of interferon-gamma release assay versus chest X-ray for tuberculosis screening of BCG-vaccinated elderly populations.
BACKGROUND
The prevalence of tuberculosis (TB) in the elderly is higher than that in the general population, and elderly populations are considered a high-risk group. Currently, annual TB screening of Bacille Calmette-Guérin (BCG)-vaccinated people aged over 65 years is performed by an annual chest x-ray examination (CXR) in Japan. Interferon-gamma release assays (QuantiFERON-TB Gold and QuantiFERON-TB Gold In-Tube [QFT]) are new alternatives to the tuberculin skin test to diagnose latent TB infection (LTBI) that have no cross-reactivity with the BCG vaccine. We evaluated the cost effectiveness of QFT versus CXR versus no screening in BCG-vaccinated elderly populations.


METHODS
We constructed a Markov model to evaluate the cost effectiveness of QFT, CXR, and no screening. The target population was a hypothetical cohort of 1000 immunocompetent 65-year-olds, using a societal perspective and a lifetime horizon. All costs and clinical benefits were discounted at a fixed annual rate of 3%.


RESULTS
In the base-case analysis, a no-screening strategy resulted in the lowest cost ($US303.51; 14.6475 quality-adjusted life-years [QALYs]) compared with CXR ($US393.22; 14.6477 QALYs) and QFT ($US525.45; 14.6516 QALYs) [year 2008 values]. The sensitivity of QFT, as well as the prevalence of TB and LTBI, influenced the cost effectiveness; when the sensitivity of QFT was higher than 0.89, QFT became more cost effective than providing no screening. As the prevalence of LTBI and TB increased, the QFT strategy became progressively more cost effective.


CONCLUSIONS
Providing no routine TB screening is currently the most cost-effective strategy for BCG-vaccinated elderly populations in Japan. There appears to be little role for CXR in TB screening of elderly populations. These findings may be applicable to other countries with intermediate and high TB risks when choosing optimal TB screening of elderly populations.
Kowada
Akiko
A
Bunkyo City Public Health Center, Bunkyo City, Tokyo, Japan. Akiko_Kowada@city.bunkyo.lg.jp
Deshpande
Gautam A
GA
Takahashi
Osamu
O
Shimbo
Takuro
T
Fukui
Tsuguya
T
D000368:Aged; D000369:Aged, 80 and over; D001500:BCG Vaccine / Q000008:administration & dosage; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D007159:Immunologic Tests / Q000191:economics*; D007371:Interferon-gamma / Q000032:analysis* / Q000276:immunology*; D007564:Japan; D055985:Latent Tuberculosis / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000276:immunology; D008297:Male; D008400:Mass Chest X-Ray / Q000191:economics*; D008403:Mass Screening / Q000191:economics; D014397:Tuberculosis, Pulmonary / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000276:immunology
D001500:BCG Vaccine; D007371:Interferon-gamma
Mol Diagn Ther. 2008;12(4):235-51
18652520
Thorax. 2010 Feb;65(2):178-80
19996345
Ann Intern Med. 1997 Dec 15;127(12):1051-61
9412307
Int J Immunopathol Pharmacol. 2009 Jul-Sep;22(3):669-77
19822083
Kekkaku. 2009 Sep;84(9):617-25
19860264
Respir Med. 2009 Dec;103(12):1838-53
19682884
Am J Respir Crit Care Med. 2003 Aug 15;168(4):443-7
12746255
Lancet. 2004 Jan 31;363(9406):345-51
15070562
Ann Intern Med. 2008 Aug 5;149(3):177-84
18593687
Ann Intern Med. 1987 Dec;107(6):843-5
3688677
Int J Tuberc Lung Dis. 2009 May;13(5):633-9
19383198
Int J Tuberc Lung Dis. 2007 Oct;11(10):1129-35
17945071
Int J Tuberc Lung Dis. 2007 Jan;11(1):16-26
17217125
Chest. 2010 Apr;137(4):952-68
20022968
Eur Respir J. 2005 Sep;26(3):465-73
16135730
Chest. 2005 Jul;128(1):116-23
16002924
Bull World Health Organ. 1982;60(4):555-64
6754120
PLoS Med. 2007 Jun;4(6):e208
17564491
Eur Respir J. 2008 Apr;31(4):842-6
18057053
N Engl J Med. 2004 May 13;350(20):2060-7
15141044
Eur Respir J. 2005 Jun;25(6):1107-16
15929967
Kekkaku. 2000 Nov;75(11):629-41
11140086
Chest. 2010 May;137(5):1057-64
19880906